Binit Aryal

This is a beautiful study, answering many of the questions we clinicians and our patients are asking: 🤔What happens if I stop the GLP1? Here's one punch line that we all could've guessed: ⭐️Exercise mitigates #weight regain when anti #obesity #medicine is stopped⭐️ But there's a lot more to observe here: 🧵1/

Can we clear arterial atherosclerotic plaques? The ACC.24 Late-Breaking Clinical Trials have been announced. My highlight is the large, phase 3, multicenter, double-blind, randomized, placebo-controlled AEGIS-II trial, a study of CSL112 (apolipoprotein A-I) infusion in patients with acute myocardial infarction. Cholesterol efflux, mediated by apolipoprotein A-I, removes excess cholesterol from atherosclerotic plaque and transports it to the liver for excretion. CSL112 increases cholesterol efflux capacity. A target sample of >18,000 participants will be randomized 1:1 to receive 4 weekly infusions of CSL112 6 g or placebo, initiated prior to or on the day of discharge and within 5 days of first medical contact. The primary outcome is the time to first occurrence of the composite of cardiovascular death, myocardial infarction, or stroke through 90 days. Why do I find it so interesting? AEGIS-II will be the first trial to formally test whether enhancing cholesterol efflux can reduce the rate of recurrent major adverse cardiovascular events. accscientificsession.acc.org/Plan-Your-Prog…

In Cardiology, one of the most feared diagnosis is a STEMI. Here are my thoughts as a cardiology fellow! Part 3: Medical Management -thread 🧵- #MedTwitter #MedEd #CardioTwitter #IMG

Baroreflex is key autonomic reflex that is dysregulated in patients with #hypertension and #heartfailure. Baroreflex stimulation therapy is now approved for the management of heart failure. Learn more ➡️ bit.ly/3XWflEa #CardioTwitter

This left atrial thrombus seems to have decided to play pinball 🤯 #MedTwitter